{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:32:25Z","timestamp":1790346745346,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["ZK [2023] General 243"],"award-info":[{"award-number":["ZK [2023] General 243"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wuhu Municipal Health Committee","award":["WHWJ2023y002"],"award-info":[{"award-number":["WHWJ2023y002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-024-02903-9","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:02:36Z","timestamp":1729209756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment"],"prefix":"10.1186","volume":"22","author":[{"given":"Wenqiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"issue":"6","key":"2903_CR1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo N, Afferi L, Moschini M, et al. Epidemiology, screening, and Prevention of bladder Cancer. Eur Urol Oncol. 2022;5(6):628\u201339. https:\/\/doi.org\/10.1016\/j.euo.2022.10.003.","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"2903_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41585-022-00611-3","volume":"19","author":"A Martin","year":"2022","unstructured":"Martin A, Woolbright BL, Umar S, Ingersoll MA, Taylor JA 3rd. Bladder cancer, inflammageing and microbiomes. Nat Rev Urol. 2022;19(8):495\u2013509. https:\/\/doi.org\/10.1038\/s41585-022-00611-3.","journal-title":"Nat Rev Urol"},{"issue":"13","key":"2903_CR3","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2002788.","journal-title":"N Engl J Med"},{"issue":"12","key":"2903_CR4","doi-asserted-by":"publisher","first-page":"111859","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton TN, Chen Z, Wise H, et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 2022;41(12):111859. https:\/\/doi.org\/10.1016\/j.celrep.2022.111859.","journal-title":"Cell Rep"},{"issue":"1","key":"2903_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3390\/pharmaceutics15010101","volume":"15","author":"H Wang","year":"2022","unstructured":"Wang H, Ewetse MP, Ma C, et al. The Light Knife for gastric Cancer: photodynamic therapy. Pharmaceutics. 2022;15(1):101. https:\/\/doi.org\/10.3390\/pharmaceutics15010101. Published 2022 Dec 28.","journal-title":"Pharmaceutics"},{"issue":"4","key":"2903_CR6","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1016\/j.clgc.2020.01.003","volume":"18","author":"E Lemke","year":"2020","unstructured":"Lemke E, Sahasrabudhe D, Guancial E, et al. The role of Metastasectomy in Urothelial Carcinoma: where are we in 2020? Clin Genitourin Cancer. 2020;18(4):e478\u201383. https:\/\/doi.org\/10.1016\/j.clgc.2020.01.003.","journal-title":"Clin Genitourin Cancer"},{"key":"2903_CR7","doi-asserted-by":"publisher","unstructured":"Li X, Lan Y, Fu X, et al. DNA nanomachine-driven chemodynamic therapy against glioblastoma. Aggregate. 2024;e603. https:\/\/doi.org\/10.1002\/agt2.603.","DOI":"10.1002\/agt2.603"},{"key":"2903_CR8","doi-asserted-by":"publisher","unstructured":"Li L, He S, Liao B et al. Orally Administrated Hydrogel Harnessing Intratumoral Microbiome and Microbiota-Related Immune responses for Potentiated Colorectal Cancer Treatment. Research (Wash D C). 2024;7:0364. Published 2024 May 8. https:\/\/doi.org\/10.34133\/research.0364","DOI":"10.34133\/research.0364"},{"key":"2903_CR9","doi-asserted-by":"publisher","first-page":"967076","DOI":"10.3389\/fimmu.2022.967076","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Deng Z, Zhao Q. Immunotherapy improves disease prognosis by affecting the tumor microenvironment: a bibliometric study. Front Immunol. 2022;13:967076. https:\/\/doi.org\/10.3389\/fimmu.2022.967076. Published 2022 Oct 6.","journal-title":"Front Immunol"},{"issue":"6","key":"2903_CR10","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/neuros\/nyaa584","volume":"88","author":"L Feldman","year":"2021","unstructured":"Feldman L, Brown C, Badie B. Chimeric Antigen receptor T-Cell therapy: updates in Glioblastoma Treatment. Neurosurgery. 2021;88(6):1056\u201364. https:\/\/doi.org\/10.1093\/neuros\/nyaa584.","journal-title":"Neurosurgery"},{"key":"2903_CR11","doi-asserted-by":"publisher","first-page":"100296","DOI":"10.1016\/j.ctarc.2020.100296","volume":"26","author":"LP Rhea","year":"2021","unstructured":"Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun. 2021;26:100296. https:\/\/doi.org\/10.1016\/j.ctarc.2020.100296.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"2903_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/cac2.12153","volume":"41","author":"J Kang","year":"2021","unstructured":"Kang J, Zhang C, Zhong WZ. Neoadjuvant immunotherapy for non-small cell lung cancer: state of the art. Cancer Commun (Lond). 2021;41(4):287\u2013302. https:\/\/doi.org\/10.1002\/cac2.12153.","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"2903_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cllc.2021.03.006","volume":"22","author":"L Cabez\u00f3n-Guti\u00e9rrez","year":"2021","unstructured":"Cabez\u00f3n-Guti\u00e9rrez L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, Khosravi-Shahi P. Biomarkers of Immune checkpoint inhibitors in Non-small Cell Lung Cancer: Beyond PD-L1. Clin Lung Cancer. 2021;22(5):381\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.006.","journal-title":"Clin Lung Cancer"},{"issue":"17","key":"2903_CR14","doi-asserted-by":"publisher","first-page":"10825","DOI":"10.3390\/ijerph191710825","volume":"19","author":"JW Yuen","year":"2022","unstructured":"Yuen JW, Wu RW, Ching SS, Ng CF. Impact of effective Intravesical therapies on Quality of Life in patients with non-muscle invasive bladder Cancer: a systematic review. Int J Environ Res Public Health. 2022;19(17):10825. https:\/\/doi.org\/10.3390\/ijerph191710825. Published 2022 Aug 30.","journal-title":"Int J Environ Res Public Health"},{"key":"2903_CR15","doi-asserted-by":"publisher","unstructured":"Shen C, Yan J, Ren Y, et al. Inhibition of proliferation, migration, and invasiveness of bladder cancer cells through SAPCD2 knockdown. Biocell. 2024;48(1). https:\/\/doi.org\/10.32604\/biocell.2023.045303.","DOI":"10.32604\/biocell.2023.045303"},{"issue":"3","key":"2903_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jncc.2023.07.002","volume":"3","author":"L Liu","year":"2023","unstructured":"Liu L, Li S, Wang G, et al. Dynamic toxicity landscape of immunotherapy for solid tumors across treatment lines. J Natl Cancer Cent. 2023;3(3):186\u201396. https:\/\/doi.org\/10.1016\/j.jncc.2023.07.002. Published 2023 Jul 15.","journal-title":"J Natl Cancer Cent"},{"issue":"4","key":"2903_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.5005\/jp-journals-10024-3322","volume":"23","author":"KKR Ealla","year":"2022","unstructured":"Ealla KKR, Veeraraghavan VP, Ravula NR, et al. Silk Hydrogel for tissue Engineering: a review. J Contemp Dent Pract. 2022;23(4):467\u201377. Published 2022 Apr 1.","journal-title":"J Contemp Dent Pract"},{"issue":"3","key":"2903_CR18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/btpr.2058","volume":"31","author":"HY Wang","year":"2015","unstructured":"Wang HY, Zhang YQ. Processing silk hydrogel and its applications in biomedical materials. Biotechnol Prog. 2015;31(3):630\u201340. https:\/\/doi.org\/10.1002\/btpr.2058.","journal-title":"Biotechnol Prog"},{"issue":"12","key":"2903_CR19","doi-asserted-by":"publisher","first-page":"e2206399","DOI":"10.1002\/advs.202206399","volume":"10","author":"M Wu","year":"2023","unstructured":"Wu M, Li H, Zhang C, et al. Silk-Gel Powered Adenoviral Vector enables Robust Genome Editing of PD-L1 to augment immunotherapy across multiple tumor models. Adv Sci (Weinh). 2023;10(12):e2206399. https:\/\/doi.org\/10.1002\/advs.202206399.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"2903_CR20","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1002\/ctm2.694","volume":"12","author":"D Jovic","year":"2022","unstructured":"Jovic D, Liang X, Zeng H, Lin L, Xu F, Luo Y. Single-cell RNA sequencing technologies and applications: a brief overview. Clin Transl Med. 2022;12(3):e694. https:\/\/doi.org\/10.1002\/ctm2.694.","journal-title":"Clin Transl Med"},{"key":"2903_CR21","doi-asserted-by":"publisher","unstructured":"Hwang B, Lee JH, Bang D. Single-cell RNA sequencing technologies and bioinformatics pipelines [published correction appears in Exp Mol Med. 2021;53(5):1005. doi: 10.1038\/s12276-021-00615-w]. Exp Mol Med. 2018;50(8):1\u201314. Published 2018 Aug 7. https:\/\/doi.org\/10.1038\/s12276-018-0071-8","DOI":"10.1038\/s12276-018-0071-8"},{"issue":"1","key":"2903_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-021-01105-2","volume":"14","author":"Y Lei","year":"2021","unstructured":"Lei Y, Tang R, Xu J, et al. Applications of single-cell sequencing in cancer research: progress and perspectives. J Hematol Oncol. 2021;14(1):91. https:\/\/doi.org\/10.1186\/s13045-021-01105-2. Published 2021 Jun 9.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2903_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41580-021-00407-0","volume":"23","author":"JG Greener","year":"2022","unstructured":"Greener JG, Kandathil SM, Moffat L, Jones DT. A guide to machine learning for biologists. Nat Rev Mol Cell Biol. 2022;23(1):40\u201355. https:\/\/doi.org\/10.1038\/s41580-021-00407-0.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"22","key":"2903_CR24","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.3390\/molecules25225277","volume":"25","author":"L Patel","year":"2020","unstructured":"Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine learning methods in Drug Discovery. Molecules. 2020;25(22):5277. https:\/\/doi.org\/10.3390\/molecules25225277. Published 2020 Nov 12.","journal-title":"Molecules"},{"key":"2903_CR25","doi-asserted-by":"publisher","unstructured":"Zeng J, Yang L, Zeng L et al. Visualizing cancer resistance via nano-quenching and recovery detector of CD44. J Nanobiotechnology. 2024;22(1):452. Published 2024 Jul 30. https:\/\/doi.org\/10.1186\/s12951-024-02732-w","DOI":"10.1186\/s12951-024-02732-w"},{"key":"2903_CR26","doi-asserted-by":"publisher","unstructured":"Wang C, Ren YL, Zhai J, Zhou XY, Wu J. Down-regulated LAMA4 inhibits oxidative stress-induced apoptosis of retinal ganglion cells through the MAPK signaling pathway in rats with glaucoma [retracted in: Cell Cycle. 2022;21(23):2551. doi: 10.1080\/15384101.2022.2097798]. Cell Cycle. 2019;18(9):932\u2013948. https:\/\/doi.org\/10.1080\/15384101.2019.1593645","DOI":"10.1080\/15384101.2019.1593645"},{"issue":"16","key":"2903_CR27","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.3390\/ijms20164042","volume":"20","author":"J Shen","year":"2019","unstructured":"Shen J, Yang D, Zhou X, et al. Role of Autophagy in Zinc Oxide nanoparticles-Induced apoptosis of mouse LEYDIG cells. Int J Mol Sci. 2019;20(16):4042. https:\/\/doi.org\/10.3390\/ijms20164042. Published 2019 Aug 19.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2903_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/medicina57080749","volume":"57","author":"J Dobruch","year":"2021","unstructured":"Dobruch J, Oszczud\u0142owski M. Bladder Cancer: current challenges and future directions. Med (Kaunas). 2021;57(8):749. https:\/\/doi.org\/10.3390\/medicina57080749. Published 2021 Jul 24.","journal-title":"Med (Kaunas)"},{"issue":"14","key":"2903_CR29","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1038\/s41388-017-0099-6","volume":"37","author":"D Fantini","year":"2018","unstructured":"Fantini D, Glaser AP, Rimar KJ, et al. A carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene. 2018;37(14):1911\u201325. https:\/\/doi.org\/10.1038\/s41388-017-0099-6.","journal-title":"Oncogene"},{"issue":"3","key":"2903_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/bioengineering10030318","volume":"10","author":"S Liu","year":"2023","unstructured":"Liu S, Chen H, Zheng Z, He Y, Yao X. Development of a Molecular-Subtype-Associated Immune Prognostic signature that can be recognized by MRI Radiomics features in bladder Cancer. Bioeng (Basel). 2023;10(3):318. https:\/\/doi.org\/10.3390\/bioengineering10030318. Published 2023 Mar 2.","journal-title":"Bioeng (Basel)"},{"issue":"6573","key":"2903_CR31","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1126\/science.abk3436","volume":"374","author":"A Melcher","year":"2021","unstructured":"Melcher A, Harrington K, Vile R. Oncolytic virotherapy as immunotherapy. Science. 2021;374(6573):1325\u20136. https:\/\/doi.org\/10.1126\/science.abk3436.","journal-title":"Science"},{"issue":"7","key":"2903_CR32","doi-asserted-by":"publisher","first-page":"e004935","DOI":"10.1136\/jitc-2022-004935","volume":"10","author":"TT Nguyen","year":"2022","unstructured":"Nguyen TT, Shin DH, Sohoni S, et al. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J Immunother Cancer. 2022;10(7):e004935. https:\/\/doi.org\/10.1136\/jitc-2022-004935.","journal-title":"J Immunother Cancer"},{"key":"2903_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","volume":"259","author":"E Oh","year":"2017","unstructured":"Oh E, Oh JE, Hong J, et al. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy. J Control Release. 2017;259:115\u201327. https:\/\/doi.org\/10.1016\/j.jconrel.2017.03.028.","journal-title":"J Control Release"},{"issue":"5","key":"2903_CR34","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/1535-7163.MCT-21-0823","volume":"21","author":"S Thongchot","year":"2022","unstructured":"Thongchot S, Jirapongwattana N, Luangwattananun P, et al. Adoptive transfer of Anti-nucleolin T cells combined with PD-L1 inhibition against Triple-negative breast Cancer. Mol Cancer Ther. 2022;21(5):727\u201339. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0823.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2903_CR35","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1021\/acs.nanolett.1c04977","volume":"22","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Wang Y, Zhao B, et al. Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade effectively restrains Orthotopic Hepatocellular Carcinoma Progression. Nano Lett. 2022;22(5):2048\u201358. https:\/\/doi.org\/10.1021\/acs.nanolett.1c04977.","journal-title":"Nano Lett"},{"key":"2903_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2018.09.037","volume":"187","author":"M Kumar","year":"2018","unstructured":"Kumar M, Gupta P, Bhattacharjee S, Nandi SK, Mandal BB. Immunomodulatory injectable silk hydrogels maintaining functional islets and promoting anti-inflammatory M2 macrophage polarization. Biomaterials. 2018;187:1\u201317. https:\/\/doi.org\/10.1016\/j.biomaterials.2018.09.037.","journal-title":"Biomaterials"},{"issue":"1","key":"2903_CR37","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1038\/s41467-020-20019-0","volume":"11","author":"Y Zheng","year":"2020","unstructured":"Zheng Y, Chen Z, Han Y, et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat Commun. 2020;11(1):6268. https:\/\/doi.org\/10.1038\/s41467-020-20019-0. Published 2020 Dec 8.","journal-title":"Nat Commun"},{"issue":"1","key":"2903_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1365-2249.2002.01813.x","volume":"128","author":"JN Pettiford","year":"2002","unstructured":"Pettiford JN, Jason J, Nwanyanwu OC, et al. Age-related differences in cell-specific cytokine production by acutely ill Malawian patients. Clin Exp Immunol. 2002;128(1):110\u20137. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01813.x.","journal-title":"Clin Exp Immunol"},{"issue":"19","key":"2903_CR39","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a Multicenter, phase ib study. J Clin Oncol. 2017;35(19):2117\u201324. https:\/\/doi.org\/10.1200\/JCO.2016.71.6795.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2903_CR40","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5.","journal-title":"Lancet Oncol"},{"issue":"8","key":"2903_CR41","doi-asserted-by":"publisher","first-page":"e29532","DOI":"10.1002\/pbc.29532","volume":"69","author":"R Akkary","year":"2022","unstructured":"Akkary R, Gu\u00e9rin F, Chargari C, et al. Long-term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder-prostate rhabdomyosarcoma: a single-team experience. Pediatr Blood Cancer. 2022;69(8):e29532. https:\/\/doi.org\/10.1002\/pbc.29532.","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"2903_CR42","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: a review. JAMA. 2020;324(19):1980\u201391. https:\/\/doi.org\/10.1001\/jama.2020.17598.","journal-title":"JAMA"},{"issue":"6 Suppl 1","key":"2903_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4\u201334. https:\/\/doi.org\/10.1016\/j.urology.2005.07.062.","journal-title":"Urology"},{"issue":"3","key":"2903_CR44","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12094-020-02442-3","volume":"23","author":"L Leon-Mateos","year":"2021","unstructured":"Leon-Mateos L, Garcia-Velloso MJ, Garc\u00eda-Figueiras R, et al. A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. Clin Transl Oncol. 2021;23(3):434\u201349. https:\/\/doi.org\/10.1007\/s12094-020-02442-3.","journal-title":"Clin Transl Oncol"},{"key":"2903_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejca.2022.07.014","volume":"174","author":"S Yoon","year":"2022","unstructured":"Yoon S, Shin SJ, Kim HC, et al. Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failure. Eur J Cancer. 2022;174:81\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.014.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2903_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323. https:\/\/doi.org\/10.3322\/caac.21631.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2903_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21(2):104\u201321. https:\/\/doi.org\/10.1038\/s41568-020-00313-1.","journal-title":"Nat Rev Cancer"},{"key":"2903_CR48","doi-asserted-by":"publisher","unstructured":"Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study [published correction appears in Lancet Oncol. 2021;22(8):e347. Doi: 10.1016\/S1470-2045(21)00414-9]. Lancet Oncol. 2021;22(7):919\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(21)00147-9.","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"2903_CR49","doi-asserted-by":"publisher","unstructured":"Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci. 2022;79(3):191. Published 2022 Mar 16. https:\/\/doi.org\/10.1007\/s00018-022-04219-z","DOI":"10.1007\/s00018-022-04219-z"},{"issue":"2","key":"2903_CR50","doi-asserted-by":"publisher","first-page":"e001749","DOI":"10.1136\/jitc-2020-001749","volume":"9","author":"H Van Damme","year":"2021","unstructured":"Van Damme H, Dombrecht B, Kiss M, et al. Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. J Immunother Cancer. 2021;9(2):e001749. https:\/\/doi.org\/10.1136\/jitc-2020-001749.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2903_CR51","doi-asserted-by":"publisher","first-page":"eabh4050","DOI":"10.1126\/sciadv.abh4050","volume":"8","author":"T Walle","year":"2022","unstructured":"Walle T, Kraske JA, Liao B, et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv. 2022;8(12):eabh4050. https:\/\/doi.org\/10.1126\/sciadv.abh4050.","journal-title":"Sci Adv"},{"issue":"9","key":"2903_CR52","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.7150\/ijms.51703","volume":"18","author":"B Shi","year":"2021","unstructured":"Shi B, Ding J, Qi J, Gu Z. Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap. Int J Med Sci. 2021;18(9):2063\u201375. https:\/\/doi.org\/10.7150\/ijms.51703. Published 2021 Mar 11.","journal-title":"Int J Med Sci"},{"issue":"10","key":"2903_CR53","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/ijc.32336","volume":"145","author":"H Iioka","year":"2019","unstructured":"Iioka H, Saito K, Sakaguchi M, Tachibana T, Homma K, Kondo E. Crumbs3 is a critical factor that regulates invasion and metastasis of colon adenocarcinoma via the specific interaction with FGFR1. Int J Cancer. 2019;145(10):2740\u201353. https:\/\/doi.org\/10.1002\/ijc.32336.","journal-title":"Int J Cancer"},{"issue":"7","key":"2903_CR54","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1111\/jcmm.13619","volume":"22","author":"P Li","year":"2018","unstructured":"Li P, Feng C, Chen H, et al. Elevated CRB3 expression suppresses breast cancer stemness by inhibiting \u03b2-catenin signalling to restore tamoxifen sensitivity. J Cell Mol Med. 2018;22(7):3423\u201333. https:\/\/doi.org\/10.1111\/jcmm.13619.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2903_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022;11(1):38. https:\/\/doi.org\/10.1186\/s40164-022-00291-0. Published 2022 Jun 20.","journal-title":"Exp Hematol Oncol"},{"key":"2903_CR56","doi-asserted-by":"publisher","unstructured":"Sui H, Zhang L, Gu K et al. YYFZBJS ameliorates colorectal cancer progression in ApcMin\/+ mice by remodeling gut microbiota and inhibiting regulatory T-cell generation. Cell Commun Signal. 2020;18(1):113. Published 2020 Jul 16. https:\/\/doi.org\/10.1186\/s12964-020-00596-9","DOI":"10.1186\/s12964-020-00596-9"},{"key":"2903_CR57","doi-asserted-by":"publisher","first-page":"101415","DOI":"10.1016\/j.smim.2020.101415","volume":"49","author":"MV Dhodapkar","year":"2020","unstructured":"Dhodapkar MV, Dhodapkar KM. Tissue-resident memory-like T cells in tumor immunity: clinical implications. Semin Immunol. 2020;49:101415. https:\/\/doi.org\/10.1016\/j.smim.2020.101415.","journal-title":"Semin Immunol"},{"issue":"1","key":"2903_CR58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","volume":"40","author":"H Zhang","year":"2021","unstructured":"Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):184. https:\/\/doi.org\/10.1186\/s13046-021-01987-7. Published 2021 Jun 4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"2903_CR59","doi-asserted-by":"publisher","first-page":"a041332","DOI":"10.1101\/cshperspect.a041332","volume":"13","author":"LA Emens","year":"2023","unstructured":"Emens LA, Loi S. Immunotherapy approaches for breast Cancer patients in 2023. Cold Spring Harb Perspect Med. 2023;13(4):a041332. https:\/\/doi.org\/10.1101\/cshperspect.a041332. Published 2023 Apr 3.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"2903_CR60","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jtho.2022.05.016","volume":"17","author":"M Reck","year":"2022","unstructured":"Reck M, Mok TSK, Mansfield A, et al. Brief report: Exploratory Analysis of Maintenance Therapy in patients with extensive-stage SCLC treated First Line with Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022;17(9):1122\u20139. https:\/\/doi.org\/10.1016\/j.jtho.2022.05.016.","journal-title":"J Thorac Oncol"},{"issue":"36","key":"2903_CR61","doi-asserted-by":"publisher","first-page":"eabb3116","DOI":"10.1126\/sciadv.abb3116","volume":"6","author":"L Qin","year":"2020","unstructured":"Qin L, Cao J, Shao K, et al. A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis. Sci Adv. 2020;6(36):eabb3116. https:\/\/doi.org\/10.1126\/sciadv.abb3116. Published 2020 Sep 4.","journal-title":"Sci Adv"},{"issue":"7","key":"2903_CR62","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.7150\/thno.42385","volume":"10","author":"X Dai","year":"2020","unstructured":"Dai X, Meng J, Deng S, et al. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel. Theranostics. 2020;10(7):3049\u201363. https:\/\/doi.org\/10.7150\/thno.42385. Published 2020 Feb 10.","journal-title":"Theranostics"},{"key":"2903_CR63","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.drup.2024.101122","volume":"76","author":"Y Lan","year":"2024","unstructured":"Lan Y, Li X, Liu B, et al. Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma. Drug Resist Updat. 2024;76:101122. https:\/\/doi.org\/10.1016\/j.drup.2024.101122.","journal-title":"Drug Resist Updat"},{"key":"2903_CR64","doi-asserted-by":"publisher","unstructured":"Ye L, Gao Y, Mok SWF et al. Modulation of alveolar macrophage and mitochondrial fitness by medicinal plant-derived nanovesicles to mitigate acute lung injury and viral pneumonia. J Nanobiotechnology. 2024;22(1):190. Published 2024 Apr 18. https:\/\/doi.org\/10.1186\/s12951-024-02473-w","DOI":"10.1186\/s12951-024-02473-w"},{"key":"2903_CR65","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3389\/fimmu.2019.00925","volume":"10","author":"S Vigano","year":"2019","unstructured":"Vigano S, Alatzoglou D, Irving M, et al. Targeting Adenosine in Cancer Immunotherapy to enhance T-Cell function. Front Immunol. 2019;10:925. https:\/\/doi.org\/10.3389\/fimmu.2019.00925. Published 2019 Jun 6.","journal-title":"Front Immunol"},{"issue":"8","key":"2903_CR66","doi-asserted-by":"publisher","first-page":"513","DOI":"10.14348\/molcells.2022.2056","volume":"45","author":"GR Kim","year":"2022","unstructured":"Kim GR, Choi JM. Current understanding of cytotoxic T lymphocyte Antigen-4 (CTLA-4) signaling in T-Cell Biology and Disease Therapy. Mol Cells. 2022;45(8):513\u201321. https:\/\/doi.org\/10.14348\/molcells.2022.2056.","journal-title":"Mol Cells"},{"issue":"7","key":"2903_CR67","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","volume":"14","author":"W Tang","year":"2023","unstructured":"Tang W, Chen J, Ji T, Cong X. TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death Dis. 2023;14(7):466. https:\/\/doi.org\/10.1038\/s41419-023-05961-3. Published 2023 Jul 26.","journal-title":"Cell Death Dis"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02903-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-024-02903-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-024-02903-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T11:08:41Z","timestamp":1729249721000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-024-02903-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2903"],"URL":"https:\/\/doi.org\/10.1186\/s12951-024-02903-9","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"15 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study protocols were approved by the Ethics Committee of Zhuhai People\u2019s Hospital (Approval no.2022LP00209) and based on the ethical principles of the Declaration of Helsinki. The animal experiments were performed strictly per the guidelines in the Guide for the Care and Use of Laboratory Animals. The protocol of animal experiments was ratified by the Institutional Animal Care and Use Committee of Zhuhai People\u2019s Hospital (Approval no.2022AE00092).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The author declares no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"638"}}